FUJIFILM Diosynth Biotechnologies plans to expand its single-use manufacturing campus in College Station, TX, through the addition of a new cGMP production facility that will double the company’s advanced therapy and vaccine manufacturing capacity in the U.S. The investment is supported by a $1.5 million Texas Enterprise Fund Award to help create approximately 150 skilled positions, including manufacturing and operations by 2024.
The investment of approximately $300 million for facility construction is part of a previously announced $850 million global capital investment package initially outlined by FUJIFILM in June 2021.

This new facility, expected to be operational by 2024, will add approximately 138,000 ft2 to the existing campus growing the site to 300,000 ft2. The new site will house multiple 500L and 2,000L bioreactors and associated purification equipment deploying single-use technology.

“As a leader in the advanced therapy market, this complements FUJIFILM Diosynth Biotechnologies’ existing global footprint which now include sites in Watertown, MA, and Darlington, U.K.,” says Martin Meeson, CEO, FUJIFILM Diosynth Biotechnologies.

“As the need for advanced therapies development and manufacturing capacity grows, we will continue to invest in the right technology and talent to support our partners in bringing to market these life-impacting medicines,” said adds Gerry Farrell, COO, FUJIFILM Diosynth Biotechnologies, Texas. “We are grateful to Governor Greg Abbott, and the State of Texas for its commitment to supporting the growth of the Texas biocorridor, and creating highly-skilled jobs in the state. We are also grateful to the cities of Bryan and College Station and Brazos County for their continued support with this initiative.”